

Supplementary Table SI: Adverse events on maintenance lenalidomide

Adverse Event	Total (N = 13)	
	Grade 1-2, n (%)	Grade 3-4, n (%)
Non-hematologic		
Fatigue	4 (31)	1 (8)
Rash	5 (38)	0
Diarrhea	2 (15)	0
Acute kidney injury	1 (8)	1 (8)
Deep vein thrombosis	0	1 (8)
Pneumonia	0	1 (8)
Hemorrhage*	0	1 (8)
Arthralgia	1 (8)	0
Hematologic		
Neutropenia	6 (46)	1 (8)
Anemia	5 (38)	2 (15)
Thrombocytopenia	5 (38)	0

*Patient developed grade 3 subdural hematoma within 1 month of starting lenalidomide, likely related to aspirin.

Table SI. Toxicities Associated with Low-Dose Lenalidomide Maintenance in Older Patients with PCNSL

Five toxicities mandated cessation of lenalidomide maintenance. Patient 3 experienced a subdural hematoma within one month, likely related to aspirin. Patient 5 experienced grade 3 fatigue after 21 months of lenalidomide maintenance, prompting cessation of therapy. Patient 6, with a history of polymyalgia rheumatica, experienced recrudescence of grade 2 arthralgias with lenalidomide. Patient 10 developed deep vein thrombosis at 1 year of lenalidomide maintenance but resumed lenalidomide after anticoagulation. Patient 11 (KPS 50 at baseline) developed pneumonia after 8 months of lenalidomide maintenance.